Concert Pharmaceuticals Valuation
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
At this time, the firm appears to be overvalued. Concert Pharmaceuticals shows a prevailing Real Value of $6.26 per share. The current price of the firm is $8.37. Our model approximates the value of Concert Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -1.09, operating margin of (2.88) %, and Shares Outstanding of 48.02 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Concert Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Concert Pharmaceuticals is based on 3 months time horizon. Increasing Concert Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Concert stock is determined by what a typical buyer is willing to pay for full or partial control of Concert Pharmaceuticals. Since Concert Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Concert Stock. However, Concert Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.37 | Real 6.26 | Hype 8.37 | Naive 8.65 |
The real value of Concert Stock, also known as its intrinsic value, is the underlying worth of Concert Pharmaceuticals Company, which is reflected in its stock price. It is based on Concert Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Concert Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Concert Pharmaceuticals helps investors to forecast how Concert stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Concert Pharmaceuticals more accurately as focusing exclusively on Concert Pharmaceuticals' fundamentals will not take into account other important factors: Concert Pharmaceuticals Total Value Analysis
Concert Pharmaceuticals is currently forecasted to have valuation of 86.63 M with market capitalization of 401.95 M, debt of 14.51 M, and cash on hands of 154.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Concert Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
86.63 M | 401.95 M | 14.51 M | 154.57 M |
Concert Pharmaceuticals Investor Information
About 77.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Concert Pharmaceuticals recorded a loss per share of 3.17. The entity had not issued any dividends in recent years. Based on the key indicators related to Concert Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Concert Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Concert Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Concert Pharmaceuticals has an asset utilization ratio of 0.0197 percent. This indicates that the Company is making $1.97E-4 for each dollar of assets. An increasing asset utilization means that Concert Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Concert Pharmaceuticals Ownership Allocation
Concert Pharmaceuticals holds a total of 48.02 Million outstanding shares. The majority of Concert Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Concert Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Concert Pharmaceuticals. Please pay attention to any change in the institutional holdings of Concert Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Concert Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 32.58 K. Net Loss for the year was (80.05 K) with loss before overhead, payroll, taxes, and interest of (54.98 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Concert Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Concert Pharmaceuticals and how it compares across the competition.
About Concert Pharmaceuticals Valuation
The delisted stock valuation mechanism determines Concert Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Concert Pharmaceuticals. We calculate exposure to Concert Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Concert Pharmaceuticals's related companies.Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Concert Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Concert Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Concert Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 34.4 M | |
| Retained Earnings | -349.5 M | |
| Retained Earnings Total Equity | -349.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |